These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38349260)

  • 1. CALCRL knockdown suppresses cancer stemness and chemoresistance in acute myeloid leukemia with FLT3-ITD and DNM3TA-R882 double mutations.
    Tang S; Zhu H; Sheng L; Mu Q; Wang Y; Xu K; Zhou M; Xu Z; Wu A; Ouyang G
    Drug Dev Res; 2024 Feb; 85(1):e22137. PubMed ID: 38349260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical Value of Translocator Protein Gene in Evaluating the Efficacy of
    Tang SH; Lu Y; Zhang PS; Chen D; Liu XH; DU XH; Cao JJ; Li SY; Sha KY; Chen LG; Zhuang XX; Ye PP; Lin L; Pei RZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):45-49. PubMed ID: 36765475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FLT3-ITD with DNMT3A R882 double mutation is a poor prognostic factor in Chinese patients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantation.
    Tang S; Shen H; Mao X; Dai H; Zhu X; Xue S; Ding Z; Lu J; Wu D; Tang X
    Int J Hematol; 2017 Oct; 106(4):552-561. PubMed ID: 28616699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of FLT3-ITD with DNMT3A R882 double-mutation on the prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
    Tang SH; Lu Y; Zhang PS; Liu XH; Du XH; Chen D; Sha KY; Li SY; Cao JJ; Chen LG; Zhuang XX; Pei RZ; Tang XW
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):552-557. PubMed ID: 30122013
    [No Abstract]   [Full Text] [Related]  

  • 5. DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.
    Ahn JS; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):61-70. PubMed ID: 26234722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.
    Guryanova OA; Shank K; Spitzer B; Luciani L; Koche RP; Garrett-Bakelman FE; Ganzel C; Durham BH; Mohanty A; Hoermann G; Rivera SA; Chramiec AG; Pronier E; Bastian L; Keller MD; Tovbin D; Loizou E; Weinstein AR; Gonzalez AR; Lieu YK; Rowe JM; Pastore F; McKenney AS; Krivtsov AV; Sperr WR; Cross JR; Mason CE; Tallman MS; Arcila ME; Abdel-Wahab O; Armstrong SA; Kubicek S; Staber PB; Gönen M; Paietta EM; Melnick AM; Nimer SD; Mukherjee S; Levine RL
    Nat Med; 2016 Dec; 22(12):1488-1495. PubMed ID: 27841873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
    Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
    Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia.
    Wakita S; Marumo A; Morita K; Kako S; Toya T; Najima Y; Doki N; Kanda J; Kuroda J; Mori S; Satake A; Usuki K; Ueki T; Uoshima N; Kobayashi Y; Kawata E; Nakayama K; Nagao Y; Shono K; Shibusawa M; Tadokoro J; Hagihara M; Uchiyama H; Uchida N; Kubota Y; Kimura S; Nagoshi H; Ichinohe T; Kurosawa S; Motomura S; Hashimoto A; Muto H; Sato E; Ogata M; Mitsuhashi K; Ando J; Tashiro H; Sakaguchi M; Yui S; Arai K; Kitano T; Miyata M; Arai H; Kanda M; Itabashi K; Fukuda T; Kanda Y; Yamaguchi H
    Cancer Sci; 2023 Apr; 114(4):1297-1308. PubMed ID: 36610002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia.
    Hu C; Zhang Y; Yang J; Xu Y; Deng T; Li Y; Xu S; Wang S; Wang P
    Cell Commun Signal; 2024 Jul; 22(1):355. PubMed ID: 38978049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations.
    Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK
    Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):82-89. PubMed ID: 29079128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Relevance of DNMT3A, FLT3 and NPM1 Mutations in Syrian Acute Myeloid Leukemia Patients.
    Moualla Y; Moassass F; Al-Halbi B; Al-Achkar W; Georgeos M; Yazigi H; Khamis A
    Asian Pac J Cancer Prev; 2022 Apr; 23(4):1387-1395. PubMed ID: 35485701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.
    El Gammal MM; Ebid GT; Madney YM; Abo-Elazm OM; Kelany AK; Torra OS; Radich JP
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e281-e290. PubMed ID: 30926392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations.
    Tang L; Huang H; Tang Y; Li Q; Wang J; Li D; Zhong Z; Zou P; You Y; Cao Y; Kong Y; Guo A; Zhou S; Li H; Meng F; Xiao Y; Zhu X
    Clin Transl Med; 2022 Sep; 12(9):e1043. PubMed ID: 36163632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shikonin Exerts an Antileukemia Effect against FLT3-ITD Mutated Acute Myeloid Leukemia Cells via Targeting FLT3 and Its Downstream Pathways.
    Zhao MN; Su L; Song F; Wei ZF; Qin TX; Zhang YW; Li W; Gao SJ
    Acta Haematol; 2024; 147(3):310-324. PubMed ID: 37926079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML.
    Garg S; Reyes-Palomares A; He L; Bergeron A; Lavallée VP; Lemieux S; Gendron P; Rohde C; Xia J; Jagdhane P; Müller-Tidow C; Lipka DB; Imren S; Humphries RK; Waskow C; Vick B; Jeremias I; Richard-Carpentier G; Hébert J; Sauvageau G; Zaugg JB; Barabé F; Pabst C
    Blood; 2019 Jul; 134(3):263-276. PubMed ID: 31076446
    [No Abstract]   [Full Text] [Related]  

  • 16. Acute myeloid leukemia patient with
    Huang Y; Hu J; Lu T; Luo Y; Shi J; Wu W; Han X; Zheng W; He J; Cai Z; Wei G; Huang H; Sun J
    Cancer Manag Res; 2019; 11():4129-4142. PubMed ID: 31190985
    [No Abstract]   [Full Text] [Related]  

  • 17. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
    Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M
    Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
    Djamai H; Berrou J; Dupont M; Kaci A; Ehlert JE; Weber H; Baruchel A; Paublant F; Prudent R; Gardin C; Dombret H; Braun T
    Leuk Res; 2021 Jan; 100():106490. PubMed ID: 33373830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FLT3-ITD drives Ara-C resistance in leukemic cells via the induction of RUNX3.
    Damdinsuren A; Matsushita H; Ito M; Tanaka M; Jin G; Tsukamoto H; Asai S; Ando K; Miyachi H
    Leuk Res; 2015 Dec; 39(12):1405-13. PubMed ID: 26475207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features and prognostic significance of DNMT3A, FLT3, and NPM1 mutations in de novo acute myeloid leukemia patients.
    Chen M; Zeng Z; Li X; Qin W; Cai X; Chen S; Lu X
    Int J Lab Hematol; 2023 Dec; 45(6):899-907. PubMed ID: 37519024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.